Comment
doi: 10.1016/S1474-4422(23)00040-6.
Antisense oligonucleotides in myotonic dystrophy type 1: lessons learnt
Affiliations
- PMID: 36804078
- DOI: 10.1016/S1474-4422(23)00040-6
Item in Clipboard
Comment
Antisense oligonucleotides in myotonic dystrophy type 1: lessons learnt
Lancet Neurol.
2023 Mar.
Erratum in
-
Correction to Lancet Neurol 2023; 22: 191-92.Lancet Neurol. 2023 Apr;22(4):e6. doi: 10.1016/S1474-4422(23)00089-3. Lancet Neurol. 2023. PMID: 36931809 No abstract available.
No abstract available
Conflict of interest statement
I declare no competing interests.
Comment on
-
Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial.Lancet Neurol. 2023 Mar;22(3):218-228. doi: 10.1016/S1474-4422(23)00001-7. Lancet Neurol. 2023. PMID: 36804094 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources